Navigation Links
TechAtlas Group Releases Hepatitis C Competitive Landscape Analysis
Date:8/21/2013

BOSTON, Aug. 21, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Hepatitis C (HCV) competitive landscape map. This particular landscape highlights 25 international companies with over 60 drugs and combinations currently on the market and in development.

(Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO )

Topics include:

  • Winning the HCV race
  • Gilead: the one to beat
  • Debate over what is "Good Enough"
  • Other nukes
  • Leading nuke-less regimens
  • Strategic Implications of Worldwide genotype distribution
  • HCV all-oral combination timeline
  • Competitive positioning and rationale for partnerships and M&A

TechAtlas' analysts have evaluated each clinical asset and combination regimen according to the parameters that dictate their commercial competitiveness, including clinical benefit/risk, cost, patient preference, and reimbursement dynamics. For example, all companies are striving to win the HCV race with an all-oral, genotype-1 or pan-genotypic regimen that is convenient (QD), well-tolerated, highly effective (>90% SVR), as short as possible (12 weeks or less), has few drug-drug interactions (DDI), and works well even in patients with subclinical cirrhosis. Such a regimen could be prescribed by primary physicians with little more information than just a confirmation that the patient has HCV and possibly the viral genotype, allowing far more patients to be treated and cured than the current limited bandwidth of specialists allows, not just in the US and Europe but also in China, Egypt, and other countries were HCV is prevalent but where medical care is not as "high-touch". If multiple regimens achieve "optimal" status, or even come close, then the leaders will be at the mercy of followers willing to cut price to gain market share. But there is going to be considerable debate over what is "good enough" such that payors could push for cost-savings without being seen as compromising patient care.

The TechAtlas map graphically presents every HCV-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs and a timeline of upcoming clinical milestones as well as expected earliest sales dates through 2017. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the hepatology and infectious disease community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

TechAtlas Group's current subscribers have reported that their researchers, business development executives, and senior management have used the maps to guide their business development efforts, R&D resource allocation, and competitive positioning.

Some of the 25 companies featured on the TechAtlas HCV landscape include: AbbVie, Achillion, BMS, Boehringer Ingelheim, Enanta, Gilead, GSK, Idenix, Johnson & Johnson, Merck, Novartis, Presidio, Roche, Scynexis and Vertex.  

For further information on obtaining a copy of this report through an annual subscription, please consult our website: http://www.techatlasgroup.com/order.html

About TechAtlas Group
TechAtlas Group, LLC brings a novel, multi-dimensional, visually stimulating approach to decision makers who are already flooded with data and information but are seeking context and actionable insight to guide their resource allocation for R&D and commercial activities. Founded in 2011, TechAtlas Group, LLC is headquartered in Boston, MA.  Their large team of PhDs is trained to analyze the viability and commercial competitiveness of a variety of technologies and distill their insights into a visual landscape.  As each field evolves, the maps are updated and issued to subscribers.  The TechAtlas mission is to convey in one dynamic diagram what has conventionally been crammed into a static 100-page report.


'/>"/>
SOURCE TechAtlas Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
2. New Survey: Hispanic Teen Drug Use Significantly Higher Than Other Ethnic Groups, Substance Abuse Becoming Normalized Behavior Among Latino Youth
3. CompuGroup Medical US Announces New Laboratory Information System for the Reference Laboratory, CGM ENDEAVOR
4. Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
6. AtlantiCare Heart Heroes group donates Cardiac Science AED to Atlantic City public access defibrillation program
7. Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
8. Linde Distributor Association, at twenty, is a leading buying group in the U.S.
9. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
10. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
11. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Cold Chain Logistics Market ... Dairy & Frozen Dessert, Meat, Fish & Sea Food, ... and Industry Forecasts, 2014-2022," projects that the global cold ... by 2022, growing at a CAGR of 16% (2016 ...
(Date:1/24/2017)... LONDON , January 24, 2017 Analysis ... End User Liquid Biopsies - our new study reveals ... biopsy market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017   ... in the engineering and industrialization of biology to improve the ... that it has entered into a definitive agreement to acquire ... clinical-stage company and pioneer in the development of AdenoVerse™ gene ... expand upon GenVec,s expertise in adenoviral vectors and cGMP drug ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate Solutions, ... Series of webinars will start January 31 with a session about understanding healthcare ... health and benefits topics, including employee engagement, pricing transparency, population health and wellness, ...
(Date:1/24/2017)... Santa Margarita, CA (PRWEB) , ... January 24, 2017 , ... ... advancement platform for 21st century leadership, has named Hector M. Chavez, Manager, Employee & ... and diabetes treatment center - as its Hispanic Leader of the Month. City of ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... Need to Thrive , Well-meaning studies such as the Fordham Institute’s High ... better serve top students, such as including gifted or high-achieving students as a ...
(Date:1/24/2017)... , ... January 24, 2017 , ... American Family Care ... expanding access to high-quality health care for residents in the area. The Bedford clinic ... opened during the past four years by Dave Adams and Dr. Kristina Orio. Adams ...
(Date:1/24/2017)... ... ... “Speaking With God’s Voice”: a resolute and spirited call for anointed preaching ... A. Miraglia, a born-again believer, who spent his years teaching high school and Sunday-school, ... “There is little doubt that God Himself prepared me for this study, and God’s ...
Breaking Medicine News(10 mins):